Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu 610041, Sichuan Province, China.
World J Gastroenterol. 2009 Nov 14;15(42):5352-9. doi: 10.3748/wjg.15.5352.
To evaluate the impact of splenectomy on long-term survival, postoperative morbidity and mortality of patients with gastric cancer by performing a meta-analysis.
A search of electronic databases to identify randomized controlled trials in The Cochrane Library trials register, Medline, CBMdisc (Chinese Biomedical Database) and J-STAGE, etc was performed. Data was extracted from the studies by 2 independent reviewers. Outcome measures were survival, postoperative morbidity and mortality and operation-related events. The meta-analyses were performed by RevMan 4.3.
Three studies comprising 466 patients were available for analysis, with 231 patients treated by gastrectomy plus splenectomy. Splenectomy could not increase the 5-year overall survival rate [RR=1.17, 95% confidence interval (CI) 0.97-1.41]. The postoperative morbidity (RR=1.76, 95% CI 0.82-3.80) or mortality (RR=1.58, 95% CI 0.45-5.50) did not suggest any significant differences between the 2 groups. No significant differences were noted in terms of number of harvested lymph nodes, operation time, length of hospital stay and reoperation rate. Subgroup analyses showed splenectomy did not increase the survival rate for proximal and whole gastric cancer. No obvious differences were observed between the 2 groups when stratified by stage. Sensitivity analyses indicated no significant differences regarding the survival rates (P>0.05).
Splenectomy did not show a beneficial effect on survival rates compared to splenic preservation. Routinely performing splenectomy should not be recommended.
通过荟萃分析评估脾切除术对胃癌患者长期生存、术后发病率和死亡率的影响。
检索 Cochrane 图书馆临床试验注册、Medline、CBMdisc(中国生物医学数据库)和 J-STAGE 等电子数据库,以确定随机对照试验。由 2 名独立评审员从研究中提取数据。结局指标为生存、术后发病率和死亡率以及与手术相关的事件。使用 RevMan 4.3 进行荟萃分析。
共有 3 项研究,包含 466 例患者,其中 231 例行胃切除术加脾切除术。脾切除术不能提高 5 年总生存率[RR=1.17,95%置信区间(CI)0.97-1.41]。术后发病率(RR=1.76,95%CI 0.82-3.80)或死亡率(RR=1.58,95%CI 0.45-5.50)在两组之间无显著差异。两组在采集的淋巴结数量、手术时间、住院时间和再次手术率方面无显著差异。亚组分析显示,脾切除术并未提高近端和全胃癌患者的生存率。按分期分层,两组间无明显差异。敏感性分析表明,生存率无显著差异(P>0.05)。
与保留脾脏相比,脾切除术对生存率没有显示出有益的效果。不建议常规进行脾切除术。